Logo

SYK

Stryker Corporation

SYK

Stryker Corporation • NYSE
$371.18 ▼ -0.30% (-1.11)
Market Cap $141.94 B
52w High $406.19
52w Low $329.16
Dividend Yield 3.36%
P/E 48.78
Volume 634.04K
Outstanding Shares 382.41M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $6.057B ▲ $2.717B ▲ $859M ▼ 14.182% ▼ $2.25 ▼ $1.363B ▼
Q2-2025 $6.022B ▲ $2.389B ▼ $884M ▲ 14.68% ▲ $2.32 ▲ $1.471B ▲
Q1-2025 $5.866B ▼ $2.501B ▲ $654M ▲ 11.149% ▲ $1.71 ▲ $1.036B ▲
Q4-2024 $6.436B ▲ $2.326B ▲ $546M ▼ 8.484% ▼ $1.43 ▼ $792M ▼
Q3-2024 $5.494B $2.185B $834M 15.18% $2.19 $1.311B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.343B ▲ $47.057B ▲ $25.272B ▲ $21.785B ▲
Q2-2025 $2.464B ▲ $46.331B ▲ $25.14B ▲ $21.191B ▲
Q1-2025 $2.409B ▼ $46.006B ▲ $25.076B ▲ $20.93B ▲
Q4-2024 $4.493B ▼ $42.971B ▼ $22.337B ▼ $20.634B ▲
Q3-2024 $4.684B $43.833B $23.684B $20.149B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $859M ▼ $1.54B ▲ $-321M ▼ $-339M ▲ $881M ▲ $1.353B ▲
Q2-2025 $884M ▲ $1.111B ▲ $-104M ▲ $-989M ▼ $55M ▲ $928M ▲
Q1-2025 $654M ▲ $250M ▼ $-4.136B ▼ $2.534B ▲ $-1.332B ▼ $127M ▼
Q4-2024 $546M ▼ $1.931B ▲ $-303M ▲ $-1.794B ▼ $-198M ▼ $1.665B ▲
Q3-2024 $834M $1.474B $-2.172B $2.653B $1.976B $1.304B

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
MedSurg
MedSurg
 $4.18Bn ▲$3.51Bn ▼$3.77Bn ▲$3.80Bn ▲
Orthopaedics
Orthopaedics
 $0 ▲$0 ▲$2.25Bn ▲$2.25Bn ▲
Orthopaedics and Spine
Orthopaedics and Spine
 $0 ▲$2.35Bn ▲$0 ▼$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Stryker’s income statement shows a clear pattern of healthy growth. Sales have increased steadily each year, and core profitability (what it makes after paying for the cost of its products and operations) has generally improved. Operating profit has moved up at a solid pace, suggesting good cost control and scale benefits. Net earnings and earnings per share have trended higher over the five‑year period, even though the latest year shows slightly lower bottom‑line profit than the prior year, likely due to higher non‑operating costs or one‑off items rather than a weakening business. Overall, the business looks like a consistent grower with resilient margins.

Balance Sheet

Balance Sheet The balance sheet looks robust and built for durability. Total assets and shareholder equity have been climbing, indicating that the company is expanding while also strengthening its capital base. Cash levels have improved in recent years, giving more financial flexibility. Stryker does use a meaningful amount of debt, but that debt load has been relatively stable rather than ballooning. The overall picture is of a company that leans on leverage as a tool for growth and acquisitions, but pairs it with rising equity and cash, which helps keep financial risk in check.

Cash Flow

Cash Flow Cash generation is a strong point. Cash from day‑to‑day operations has grown over time, and after spending on equipment and facilities, Stryker still produces solid and rising free cash flow. Capital spending has ticked up, which is consistent with a company investing in new technology, manufacturing, and innovation. The combination of growing operating cash and disciplined investment suggests Stryker has room to fund research, acquisitions, and shareholder returns without stretching its finances.

Competitive Edge

Competitive Edge Stryker holds a very strong competitive position in medical devices, especially in orthopedics and surgical technologies. Its presence spans many product categories, making it an important partner for hospitals and surgical centers. The Mako robotics platform and other advanced systems create high switching costs: once surgeons are trained and workflows are built around Stryker tools, moving to a rival is disruptive and expensive. A well‑known brand, a large installed base, extensive training and support, and a history of successful acquisitions all reinforce its moat. The main ongoing risks are intense competition in medtech, pricing pressure from healthcare systems, and the need to keep products clinically differentiated.

Innovation and R&D

Innovation and R&D Innovation is a central pillar of Stryker’s strategy. The Mako SmartRobotics system and Tritanium 3D‑printed implants are standout examples where technology directly enhances surgical precision, patient outcomes, and customer loyalty. Stryker is also layering in digital tools, data analytics, smart operating rooms, and connected hospital systems, which deepen its integration into clinical workflows. Its approach to R&D is complemented by targeted acquisitions that add new technologies and expand into adjacent procedures, such as soft tissue fixation and trauma systems. The opportunity is to keep extending robotics and digital solutions into more procedures and care settings, while the key risk is that competitors and new technologies could narrow its lead if it under‑invests or mis-executes.

Summary

Stryker appears to be a well‑established, innovation‑driven medical technology company with a long track record of growth. Revenues and core profits have risen steadily, backed by robust cash flows and a balance sheet that supports both investment and acquisitions. Its competitive strengths come from differentiated technologies like Mako, strong surgeon relationships, a broad product lineup, and high switching costs. At the same time, the business operates in a demanding environment: hospitals face budget constraints, regulators and payers scrutinize outcomes and pricing, and rival device makers are also pushing robotics and digital tools. Future performance will hinge on Stryker’s ability to sustain clinical advantages, manage its debt prudently, and keep turning its technology pipeline into products that hospitals and surgeons view as essential rather than optional.

NEWS

October 30, 2025 · 4:05 PM UTC

Stryker reports third quarter 2025 operating results

Read more

October 14, 2025 · 8:10 AM UTC

Stryker to Feature Expanding Trauma Portfolio at the Orthopaedic Trauma Association Annual Meeting 2025

Read more

October 1, 2025 · 8:00 AM UTC

Stryker to announce financial results for its third quarter of fiscal year 2025

Read more

September 9, 2025 · 7:20 AM UTC

Stryker Launches Incompass Total Ankle System at AOFAS 2025

Read more